Captopril Reduced Plasminogen Activator Inhibitor Activity in Patients with Acute Myocardial Infarction

Japanese Circulation Journal

Volumn 61, Issue 4, 1997, Pages 308-314

  Moriyama, Yasushi ^a   Ogawa, Hisao ^a   Oshima, Shuich ^a   Takazoe, Keiji ^a   Honda, Yoshio ^a   Hirashima, Osamu ^a   Arai, Hidekazu ^a   Sakamoto, Tomohiro ^a,b   Sumida, Hitoshi ^a,b   Suefuji, Hisakazu ^a,b   Kaikita, Koichi ^a,b   Yasue, Hirofumi ^a,b  

^a Fukuoka Tokusyukai Hospital   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Captopril; Myocardial infarction; Plasminogen activator inhibitor

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CORONARY ARTERY THROMBOSIS; CORONARY RISK; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FIBRINOLYSIS; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CAPTOPRIL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030940735     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.61.308     Document Type: Article

References (35)

1. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
2. Pfeller M. A., Braunwald E., Moye L.A. et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 676-677.
3. Williams G. H., Hollenberg N. K.: Accentuated vascular and endocrine response to SQ 20, 881 in hypertension. N Engl J Med 1977; 297: 194.
4. Ridker P. M., Gaboury C. L., Conlin P. R., Seely E. W., Williams G. H., Vaughan D. E.: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin I. I.: Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-1973.
5. Dewood M. A., Spore J., Notsuke R., Mouser L. T., Burrough R., Golden MS et al: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
6. Rentrop K. P.: Thrombolytic therapy in patients with acute myocardial infarction. Circulation 1985; 71: 627—631.
7. Vermylen J. G., Chamone A. F.: The role of fibrinolytic system in thromboembolism. Prog Cardiovasc Dis 1979; 21: 255-266.
8. Zamarron J. G., Lijnen H. R., Collen D.: Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. J Biol Chem 1984; 259: 2080-2083.
9. Sprengers E. D., Kluft C.: Plasminogen activator inhibitors. Blood 1987; 69: 381-387.
10. Hamsten A., Wiman B., DeFaire U., Blomback M.: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563.
11. Hamsten A., DeFaire U., Walldius G., Dahlen G., Szamosi A., Landou C et al: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
12. Ridker P. M., Vaughan D. E., Stampfer M. J., Manson J. E., Hen-nekens C. H.: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168.
13. Munkvad S., Gram J., Jespersen J.: A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 1990; 11: 525-528.
14. Jansson J. H., Nilsson T. K., Olofsson B. O.: Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991; 12: 157-161.
15. Gram J., Jespersen J.: A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterizes a risk group among survivors of acute myocardial infarction. Thromb Haemost 1987; 57: 137-139.
16. Jansson J. H., Olofsson B. O., Nilsson T. K.: Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: A 7 year follow up. Circulation 1993; 88: 2030-2034.
17. Wright R. A., Flapan A. D., Alberti K.G.M., Ludlam C. A., Fox KAA: Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73.
18. Masuda T., Ogawa H., Miyao Y., Yu Q., Misumi I., Sakamoto T et al: Circadian variation in fibrinolytic activity in patients with variant angina. Br Heart J 1994; 71: 156-161.
19. Amiral J., Plassart V., Grosley M., Mimllla F., Contant G., Guyader AM: Measurement of rPA and t-PA-PAI complexes by ELISA, using monoclonal antibodies: Clinical relevance. Thromb Res 1988; Suppl VIII: 99-113.
20. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429.
21. Packer M., Lee W. H., Yushak M., Medina N.: Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986; 315: 847-853.
22. Pfeffer J. M., Pfeffer M., Braunwald E.: Influence of chronic captopril treatment on the infarcted left ventricle of the rat. Circ to 1985; 57: 84-95.
23. Raya T. E., Gay P. G., Aguirre M., Goldmann S.: Importance of venodilation in prevention of left ventricular dilation after chronic large myocardial infarction in rats. Circ Res 1989; 64: 330-337.
24. Sharpe N., Murphy J., Smith H., Hannah S.: Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988; 1: 255—259.
25. Pfeffer M. A., Lamas G. A., Vauchan D. E., Paresi A. F., Braunwald E.: Effects of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med 1988; 319: 80-86.
26. Liang C. S., Gravas H., Hood W. B.: Renin-angiotensin system inhibition in conscious sodium depleted dogs: Effect on systemic and coronary hemodynamics. J Clin Invest 1978; 62: 874-883.
27. Sɸgaard P., Gɸtzsche C. O., Ravkilde J., Thygesen K.: Effects of captopril on ischemia and dysfunction of the left ventricle after myocardial infarction. Circulation 1993; 87: 1093-1099.
28. Kruithof E.K.O., Gudinchet A., Bachmann F.: Plasminogen activator inhibitor I and plasminogen activator 2 in various disease states. Thromb Haemost 1988; 59: 7—12.
29. Olofsson B. O., Dahlen G., Nilsson T. K.: Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77-82.
30. Gram J., Kluft C., Jesperson J.: Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibitor and acute phase reactions in blood of patients with acute myocardial infarction (AMI). Thromb Haemost 1987; 58: 817-821.
31. Shrape N., Smith H., Murphy J., Greaves S., Hart H., Gamble G.: Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition. Lancet 1991; 337: 872-876.
32. Oldroyd K. G., Pye M. P., Ray S. G., Christie J., Ford L., Cobbe SM et al: Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. Am J Cardiol 1991; 68: 713-718.
33. Swedberg K., Held P., Kjekshus J., Rasmussen K., Ryden L., Wedel H.: On behalf of the CONSENSUS II Study Group: Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992; 327: 678-684.
34. Alderman M. H., Madhavwn S., Ool W. L., Cohen H., Sealey J., Laragh J. H.: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-1104.
35. James I. M., Dickenson E. J., Burgoyne W., Jeremy J. Y., Barra-das M. A., Mikhailidis DP et al: Treatment of hypertension with captopril: Preservation of regional blood flow and reduced platelet aggregation. J Hum Hypertens 1988; 2: 21-55.